Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.

  title={Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.},
  author={J. Alexieva-Figusch and Marinus A. Blankenstein and Wim C. J. Hop and Jan G. M. Klijn and Steven W. J. Lamberts and Frank H de Jong and Roelof Docter and Herman C Adlercreutz and H. A. van Gilse},
  journal={European journal of cancer \& clinical oncology},
  volume={20 1},
High-dose megestrol acetate in the treatment of advanced breast cancer.
The data indicate that high-dose megestrol acetate is well tolerated and effective in patients with advanced breast cancer refractory to multiple previous therapies and suggest that doses higher than the standard dose may be more effective.
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
  • J. Abrams, J. Aisner, L. Norton
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
With a median follow-up of 8 years, these results demonstrate no advantage for dose escalation of MA in the treatment of metastatic breast cancer.
A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer
A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer and a randomized trial to determine the optimal dose is ongoing.
Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study)
The progestin megestrol acetate and the anti-estrogen tamoxifen are used as effective drugs in the treatment of metastatic breast cancer and have few side effects. The sequence and indications for
Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer
TAM and MA are both equally effective in response induction as initial treatments and the combination has no advantage, and Sequential treatment is still optimal, TAM being the preferred initial agent in view of the reported side effects with MA.
Tamoxifen and megestrol acetate for postmenopausal breast cancer
The different effects on anabolic/catabolic balance and adrenal function may relate to certain clinical effects during treatment.
Oral high-dose progestins as treatment for advanced breast cancer.
A long disease-free interval, and positive receptor status of primary or metastatic lesions seemed to predict response to endocrine therapy even late in a therapeutic sequence, found in postmenopausal, previously treated advanced breast cancer patients.


Progestin therapy in advanced breast cancer: Megestrol acetate—an evaluation of 160 treated cases
Megesterol acetate therapy may be the first choice of treatment in late postmenopausal patients with soft tissue and lung metastases and no great differences in remission rates were found between patients treated with megestrol acetate as the first hormonal treatment and those previously treated with hormones.
Further clinical studies with megestrol acetate in advanced breast cancer
Megestrol acetate is included, often as the initial hormonal trial in postmenopausal patients, in the sequential treatment of disseminated breast cancer because of its favorable therapeutic ratio.
The Effect of Large Doses of Medroxyprogesterone Acetate (MPA) on Urinary Estrogen Levels and Serum Levels of Cortisol T4 LH and Testosterone in Patients With Advanced Cancer
Sixteen patients with advanced cancer were given medroxyprogesterone acetate (MPA),* 600 mg intramuscularly weekly for 4–8 weeks, suggesting that MPA, like testosterone, may be converted to estrogen in vivo.
Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma
It is concluded that this variation in plasma levels may be reflected in the clinical efficacy of the treatment of endometrial adenocarcinoma and further studies in which plasma values and clinical effectiveness are correlated seem to be indicated.
The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.
MPA has cortisol-like effects and the suppression of adrenal function is probably mediated by a negative feedback action on the hypothalamus or pituitary, and a blunted response to maximal ACTH stimulation was found.
Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen
It is suggested that megestrol acetate is an effective agent for the palliation of advanced breast cancer relapsing following response to tamoxifen therapy.
Steroid receptors in megestrol acetate therapy.
It was demonstrated that megestrol and medroxyprogesterone acetates are strong competitors for steroids which bind specifically to androgen, glucocorticoid, and progesterone receptors, indicating that these progestins are able to bind to these receptors with high affinity.
  • P. W. Adams, V. Wynn
  • Medicine, Biology
    The Journal of obstetrics and gynaecology of the British Commonwealth
  • 1972
It is concluded that the daily administration of 0.5 mg.
Evidence for the Hypothalamic Origin of the Polycystic Ovary Syndrome
The suppression of all the peripheral abnormalities of the reproductive system in polycystic ovary syndrome with MPA treatment suggests a primary hypothalamic disorder as the cause for the syndrome.